Botulinum Toxin Type A

Identification

Name
Botulinum Toxin Type A
Accession Number
DB00083  (BTD00092, BIOD00092)
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.

Protein structure
Db00083
Protein chemical formula
C6760H10447N1743O2010S32
Protein average weight
149322.7 Da
Sequences
>Botulinum Toxin Type A Sequence
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
Download FASTA Format
Synonyms
  • AbobotulinumtoxinA
  • BoNT/A
  • Bontoxilysin A
  • Botulinum neurotoxin type A precursor
  • BTX-A
  • IncobotulinumtoxinA
  • OnabotulinumtoxinA
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BotoxInjection, powder, lyophilized, for solution200 [USP'U]/1Intradermal; IntramuscularAllergan2010-01-11Not applicableUs
BotoxPowder, for solution100 unitIntramuscularAllergan1992-12-31Not applicableCanada
BotoxInjection, powder, lyophilized, for solution100 [USP'U]/1Intradermal; IntramuscularAllergan1989-12-15Not applicableUs
BOTOX CosmeticInjection, powder, lyophilized, for solution50 [USP'U]/1IntramuscularAllergan2008-07-15Not applicableUs
BOTOX CosmeticInjection, powder, lyophilized, for solution100 [USP'U]/1IntramuscularAllergan2008-05-20Not applicableUs
BOTOX CosmeticPowder, for solution100 unitIntramuscularAllergan2001-05-07Not applicableCanada
DysportInjection, powder, lyophilized, for solution500 U/1IntramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not applicableUs
DysportInjection, powder, lyophilized, for solution300 U/1IntramuscularGalderma2009-11-02Not applicableUs
DysportInjection, powder, lyophilized, for solution300 U/1IntramuscularIpsen Biopharmaceuticals, Inc.2009-11-02Not applicableUs
Dysport AestheticPowder, for solution300 unitIntramuscularIpsen Biopharm Limited2013-02-19Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ProtoxinBotulinum Toxin Type A (10 g/10mL)GelTopicalProtox Inc.2016-11-10Not applicableUs
Categories
UNII
E211KPY694
CAS number
93384-43-1

Pharmacology

Indication

For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.

Associated Conditions
Associated Therapies
Pharmacodynamics

A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.

Mechanism of action

Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.

TargetActionsOrganism
ASynaptosomal-associated protein 25
inhibitor
Human
URho-related GTP-binding protein RhoBNot AvailableHuman
Absorption

The chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Based on toxicological studies, it has been estimated that the human LD50 by injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AclidiniumAclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
AlcuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Alcuronium.Experimental
AmikacinAmikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational, Vet Approved
Anisotropine MethylbromideAnisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
ApramycinApramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental, Vet Approved
ArbekacinArbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
AtracuriumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateBotulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AtropineAtropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Vet Approved
BekanamycinBekanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
BenactyzineBenactyzine may increase the anticholinergic activities of Botulinum Toxin Type A.Withdrawn
BenzatropineBenzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
BiperidenBiperiden may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
BornaprineBornaprine may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
Botulinum Toxin Type BBotulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.Approved, Investigational
ButylscopolamineButylscopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational, Vet Approved
ChlorphenoxamineChlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type A.Withdrawn
CisatracuriumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium.Approved
CyclopentolateCyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
DarifenacinDarifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
DecamethoniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.Approved
DesloratadineDesloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
DexetimideDexetimide may increase the anticholinergic activities of Botulinum Toxin Type A.Withdrawn
DibekacinDibekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
DicyclomineDicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
DihydrostreptomycinDihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational, Vet Approved
DiphenhydramineDiphenhydramine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Domoic AcidBotulinum Toxin Type A may increase the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chlorideBotulinum Toxin Type A may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
EmeproniumEmepronium may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
EtanautineEtanautine may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
EthopropazineEthopropazine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
EtybenzatropineEtybenzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
FesoterodineFesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
FlavoxateFlavoxate may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
FramycetinFramycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved
GallamineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideBotulinum Toxin Type A may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinGeneticin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
GentamicinGentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
GlycopyrroniumGlycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational, Vet Approved
HomatropineHomatropine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
Hygromycin BHygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Vet Approved
HyoscyamineHyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
IpratropiumIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
IsepamicinIsepamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
KanamycinKanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational, Vet Approved
LorpiprazoleThe therapeutic efficacy of Botulinum Toxin Type A can be increased when used in combination with Lorpiprazole.Approved
MazaticolMazaticol may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
MecamylamineMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
MethanthelineMethantheline may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
MethscopolamineMethscopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
Methylscopolamine bromideMethylscopolamine bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
MetixeneMetixene may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
MetocurineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideBotulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MicronomicinMicronomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
MivacuriumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.Approved
NeamineNeamine may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
NeomycinNeomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
NeosaxitoxinBotulinum Toxin Type A may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NetilmicinNetilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
OrphenadrineOrphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
OtiloniumOtilonium may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental, Investigational
OxitropiumOxitropium may increase the anticholinergic activities of Botulinum Toxin Type A.Investigational
OxybutyninOxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
OxyphenoniumOxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PancuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.Approved
ParomomycinParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
PentoliniumPentolinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PhenglutarimidePhenglutarimide may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
PipecuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirenzepinePirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PlazomicinPlazomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
ProcyclidineProcyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PropanthelinePropantheline may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
PropiverinePropiverine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
PuromycinPuromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Experimental
PyrantelBotulinum Toxin Type A may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinidineQuinidine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
RapacuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RibostamycinRibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
RocuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Rocuronium.Approved
ScopolamineScopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
SisomicinSisomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Investigational
SolifenacinSolifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
StreptomycinStreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Vet Approved
SuccinylcholineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.Approved
TiotropiumTiotropium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TobramycinTobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
TolterodineTolterodine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
TrihexyphenidylTrihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TrimethaphanTrimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
TropatepineTropatepine may increase the anticholinergic activities of Botulinum Toxin Type A.Experimental
TropicamideTropicamide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
TrospiumTrospium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
TubocurarineBotulinum Toxin Type A may increase the neuromuscular blocking activities of Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved
VecuroniumBotulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.Approved
Food Interactions
Not Available

References

General References
  1. Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. [PubMed:15907915]
  2. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. [PubMed:10534247]
  3. Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. [PubMed:15839401]
  4. Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. [PubMed:15887434]
  5. Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. [PubMed:15928517]
External Links
UniProt
P10845
Genbank
X52066
KEGG Drug
D00783
KEGG Compound
C07946
PubChem Substance
46505347
Therapeutic Targets Database
DAP001298
PharmGKB
PA164754825
RxList
RxList Drug Page
Wikipedia
Botox
ATC Codes
M03AX01 — Botulinum toxin
AHFS Codes
  • 92:92.00 — Other Miscellaneous Therapeutic Agents
FDA label
Download (115 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentBladder Pain Syndrome1
0CompletedTreatmentStrokes1
0Not Yet RecruitingTreatmentGummy Smile Due to Hypermobile Upper Lip1
0RecruitingTreatmentSecondary Headache Disorder1
0TerminatedTreatmentNeurocostal neuralgia1
0WithdrawnDiagnosticBenign Prostatic Hyperplasia (BPH) / Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS) / Prostate Cancer1
1Active Not RecruitingTreatmentPruritus1
1CompletedOtherPsoriasis Vulgaris1
1CompletedTreatmentBMI >30 kg/m22
1CompletedTreatmentCerebral Palsy (CP) / Spasticity1
1CompletedTreatmentDry Eye Syndromes1
1CompletedTreatmentHyperhidrosis1
1CompletedTreatmentKnee Osteoarthritis (Knee OA)1
1CompletedTreatmentScrotal Pain1
1CompletedTreatmentVaginismus1
1CompletedTreatmentVasculogenic Erectile Dysfunction1
1CompletedTreatmentWound; Abdomen, Abdominal Wall1
1Not Yet RecruitingTreatmentHyperhidrosis1
1Not Yet RecruitingTreatmentParkinson's Disease (PD)1
1RecruitingBasic ScienceHealthy Volunteers2
1RecruitingTreatmentBotulinum Toxins, Type A / Plantar Fascitis1
1RecruitingTreatmentCervical Pain / Low Back Pain (LBP)1
1RecruitingTreatmentDepression / Parkinson's Disease (PD)1
1RecruitingTreatmentMyofascial Pain Syndromes / Myofascial Trigger Point Pain / Trigger Point Pain, Myofascial1
1RecruitingTreatmentOveractive Bladder1
1Unknown StatusTreatmentThoracic Outlet Syndrome1
1WithdrawnTreatmentBruxism / Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint / Temporomandibular Joint Disorders / Temporomandibular Joint Dysfunction Syndrome1
1WithdrawnTreatmentTorticollis1
1, 2Active Not RecruitingPreventionNonvalvular Atrial Fibrillation1
1, 2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
1, 2CompletedTreatmentCervical Dystonia / Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)1
1, 2CompletedTreatmentCluster Headache1
1, 2CompletedTreatmentDetrusor Hyperreflexia / Detrusor Instability / Overactive Bladder1
1, 2CompletedTreatmentMigraine Disorders1
1, 2CompletedTreatmentOral Dystonia / Tardive Dystonia1
1, 2CompletedTreatmentOsteoarthritis (OA)1
1, 2Not Yet RecruitingTreatmentAbnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus / Cervical Dystonia Adults 1
1, 2Not Yet RecruitingTreatmentChronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer1
1, 2Not Yet RecruitingTreatmentIncreased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors / Upper Limb Spasticity Unilaterally in Adults With History of Stroke1
1, 2RecruitingTreatmentCleft Lip / Cleft Palates / Scarring1
1, 2RecruitingTreatmentCluster Headache1
1, 2RecruitingTreatmentHeadache Disorders / Trigeminal Neuralgia (TN)1
1, 2TerminatedTreatmentEmpty Nose Syndrome / Rhinitis, Atrophic1
1, 2Unknown StatusTreatmentUrge Urinary Incontinence1
2Active Not RecruitingTreatmentObesity, Morbid1
2Active Not RecruitingTreatmentRaynaud's Disease1
2Active Not RecruitingTreatmentTremors1
2CompletedPreventionMigraines1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Sialorrhea1
2CompletedTreatmentAnal Fissures1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)3
2CompletedTreatmentBlepharospasm1
2CompletedTreatmentBotulinum Toxins, Type A1
2CompletedTreatmentBurning Mouth Syndrome1
2CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
2CompletedTreatmentCerebral Palsy (CP)1
2CompletedTreatmentCerebral Palsy (CP) / Equine and Equinovarus Foot Deformation / Spastic Paraplegia and Hemiparesis1
2CompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity1
2CompletedTreatmentCervical Dystonia2
2CompletedTreatmentCervicogenic Headaches1
2CompletedTreatmentChronic Pain Syndrome / Prostatitis1
2CompletedTreatmentChronic Testicular Pain1
2CompletedTreatmentCrows Feet / Facial Wrinkles / Lateral Canthal Lines3
2CompletedTreatmentCrows Feet / Lateral Canthal Lines1
2CompletedTreatmentCutaneous Leiomyomas / Hereditary Leiomyomatosis and Renal Cell Cancer1
2CompletedTreatmentDementias / Paratonia1
2CompletedTreatmentDepression2
2CompletedTreatmentDetrusor Muscle Hyperactivity1
2CompletedTreatmentDiabetes Mellitus (DM) / Muscle Cramps Aggravated1
2CompletedTreatmentEssential Tremor of the Upper Limbs1
2CompletedTreatmentFacial Rhytids1
2CompletedTreatmentGlabellar Frown Lines3
2CompletedTreatmentHyperhidrosis1
2CompletedTreatmentInterstitial Cystitis1
2CompletedTreatmentLacrimation increased1
2CompletedTreatmentLateral Canthal Lines1
2CompletedTreatmentLow Anterior Resection Syndrome / Rectal Carcinoma1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentMasticatory Muscles, Hypertrophy of1
2CompletedTreatmentMotor Neurone Disease / Muscle Spasticity / Strokes1
2CompletedTreatmentMuscle Contracture / Muscle Spasticity / Strokes1
2CompletedTreatmentMuscle Spasticity / Strokes2
2CompletedTreatmentMyofascial Pain Syndromes2
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentOveractive Bladder3
2CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)1
2CompletedTreatmentPain of the knee1
2CompletedTreatmentParkinson / Tremors1
2CompletedTreatmentPostherpetic Neuralgia1
2CompletedTreatmentProctalgia1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2CompletedTreatmentSialorrhea1
2CompletedTreatmentSkin Aging1
2CompletedTreatmentStomach Neoplasms1
2CompletedTreatmentThoracic Outlet Syndrome1
2Enrolling by InvitationPreventionPost-operative Excessive Scarring1
2Enrolling by InvitationTreatmentScrotal Pain1
2Not Yet RecruitingTreatmentBenign Masseteric Hypertrophy1
2Not Yet RecruitingTreatmentGroin Injury / Tendinopathy1
2Not Yet RecruitingTreatmentTemporo-Myofascial Disorder1
2RecruitingSupportive CareOesophageal Carcinoma1
2RecruitingTreatmentAtrial Flutter1
2RecruitingTreatmentBenign Prostatic Hyperplasia (BPH) / Lower Urinary Track Symptoms1
2RecruitingTreatmentBladder Pain Syndrome1
2RecruitingTreatmentBorderline Personality Disorder (BPD)1
2RecruitingTreatmentCerebral Palsy, Spastic / Pain1
2RecruitingTreatmentCervical Dystonia1
2RecruitingTreatmentChronic Diseases / Migraine Disorders1
2RecruitingTreatmentChronic Diseases / Nasal Polyposis / Rhinitis1
2RecruitingTreatmentDystonias1
2RecruitingTreatmentFacial Pain1
2RecruitingTreatmentHyperhidrosis1
2RecruitingTreatmentHypertrophy of Masseter Muscle1
2RecruitingTreatmentMigraine Disorders / Migrainous Headache / Pediatrics1
2RecruitingTreatmentNeuropathic Back Pain / Spinal Cord Injuries (SCI)1
2RecruitingTreatmentObstructed Defecation Syndrome (ODS)1
2RecruitingTreatmentOveractive Bladder With Urinary Incontinence / Urinary Incontinence (UI)1
2RecruitingTreatmentParkinson's Disease (PD)1
2RecruitingTreatmentPeyronie's Disease1
2RecruitingTreatmentPost-Operative Pain1
2RecruitingTreatmentPremature Ejaculation1
2RecruitingTreatmentRotator Cuff Tear Arthropathy1
2RecruitingTreatmentTremor, Essential1
2RecruitingTreatmentTrigeminal Neuralgia (TN)1
2TerminatedTreatmentAcne Vulgaris1
2TerminatedTreatmentAllodynia / Pain, Neuropathic1
2TerminatedTreatmentBlepharospasm1
2TerminatedTreatmentCerebral Palsy (CP)1
2TerminatedTreatmentHabitual Snoring1
2TerminatedTreatmentLower Back Pain1
2TerminatedTreatmentNeurogenic Bladder Dysfunction Nos / Spinal Cord Injuries (SCI)1
2TerminatedTreatmentNew Daily Persistent Headache1
2TerminatedTreatmentOveractive Bladder2
2TerminatedTreatmentPain1
2Unknown StatusPreventionScarring1
2Unknown StatusTreatmentArthritis / Pain1
2Unknown StatusTreatmentEpidermolysis Bullosa Simplex1
2Unknown StatusTreatmentHemifacial Spasm1
2Unknown StatusTreatmentRosaceas1
2WithdrawnTreatmentAmyotrophic Lateral Sclerosis (ALS) / Parkinson's Disease (PD)1
2WithdrawnTreatmentContact Ulcer of Vocal Folds / Granuloma / Granuloma of Vocal Cords / Granuloma, Laryngeal1
2WithdrawnTreatmentLower Urinary Tract Symptoms (LUTS) / Prostate Cancer / Radioactive Seed Implantation1
2WithdrawnTreatmentNeuroma1
2WithdrawnTreatmentOveractive Bladder / Urinary Incontinence (UI)1
2, 3CompletedPreventionScarring1
2, 3CompletedTreatmentBenign Prostatic Enlargement (BPE) / Benign Prostatic Hyperplasia (BPH)1
2, 3CompletedTreatmentChronic Plantar Fasciitis1
2, 3CompletedTreatmentFowler's Syndrome / Urinary Retention1
2, 3CompletedTreatmentRecalcitrant Alopecia Totalis / Recalcitrant Alopecia Universalis1
2, 3CompletedTreatmentRefractory Migraine1
2, 3CompletedTreatmentSialorrhea1
2, 3Not Yet RecruitingTreatmentBase-of-thumb Osteoarthritis1
2, 3Not Yet RecruitingTreatmentEpidermolysis Bullosa Simplex1
2, 3RecruitingTreatmentBlepharospasm1
2, 3RecruitingTreatmentCrows Feet Lines1
2, 3RecruitingTreatmentErectile Dysfunction (ED) / Sexual Dysfunctions1
2, 3TerminatedTreatmentPrimary Focal Hyperhidrosis of the Hands1
2, 3Unknown StatusPreventionForward Head Posture With Associated Episodic Headache Disorder1
2, 3Unknown StatusTreatmentCerebral Palsy (CP) / Sialorrhea1
2, 3Unknown StatusTreatmentLower Limb Spasticity After Stroke1
2, 3Unknown StatusTreatmentNon-relaxing Puborectalis Syndrome1
2, 3Unknown StatusTreatmentOveractive Bladder1
3Active Not RecruitingTreatmentCOMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO1
3Active Not RecruitingTreatmentCerebral Palsy (CP) / Chronic Troublesome Sialorrhea / Disability, Intellectual / Strokes / Traumatic Brain Injury (TBI)1
3Active Not RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics1
3Active Not RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics / Strokes1
3Active Not RecruitingTreatmentCerebral Palsy (CP) / Spasticity1
3Active Not RecruitingTreatmentUpper Limb Spasticity (Altered Skeletal Muscle Performance) in Children1
3Active Not RecruitingTreatmentUrinary Incontinence (UI)1
3CompletedNot AvailableAging1
3CompletedSupportive CareBRCA1 Mutations / BRCA2 Mutation / Breast Diseases / Cancer, Breast / Neoplasms / Postoperative pain1
3CompletedSupportive CareStroke With Hemiparesis1
3CompletedTreatmentAllodynia / Headaches1
3CompletedTreatmentBilateral Blepharospasm (BEB)1
3CompletedTreatmentBlepharospasm2
3CompletedTreatmentCanthal Lines1
3CompletedTreatmentCerebral Palsy (CP)1
3CompletedTreatmentCerebral Palsy (CP) / Children / Muscle Spasticity2
3CompletedTreatmentCerebrovascular Accidents3
3CompletedTreatmentCervical Dystonia5
3CompletedTreatmentChronic Low-back Pain1
3CompletedTreatmentChronic Troublesome Sialorrhea / Parkinson's Disease (PD) / Post-stroke / Traumatic Brain Injury (TBI)1
3CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines2
3CompletedTreatmentCrow's Feet Lines / Frown Lines / Glabellar Lines / Upper Facial Rhytides1
3CompletedTreatmentCrow's Feet Lines / Lateral Canthal Lines1
3CompletedTreatmentCrow's Feet Lines / Lateral Canthus Rhytides2
3CompletedTreatmentDisseminated Sclerosis / Neurogenic Bladder Dysfunction / Urinary Incontinence (UI)1
3CompletedTreatmentDisseminated Sclerosis / Tremors1
3CompletedTreatmentEssential Blepharospasm2
3CompletedTreatmentFacial Rhytides / Glabellar Rhytides1
3CompletedTreatmentForehead Rhytides / Glabellar Rhytides1
3CompletedTreatmentFrown Lines Between the Eyebrows / Glabellar Rhytides1
3CompletedTreatmentGlabellar Frown Lines1
3CompletedTreatmentGlabellar Lines4
3CompletedTreatmentGlabellar Lines / Moderate to Severe Glabellar Lines1
3CompletedTreatmentGlabellar Rhytides2
3CompletedTreatmentHyperhidrosis1
3CompletedTreatmentLateral Epicondylitis1
3CompletedTreatmentLateral Periorbital Wrinkles1
3CompletedTreatmentLeg Spasticity1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentLower Extremity Deformities, Congenital / Unequal Length of Limbs; Congenital1
3CompletedTreatmentLower Limb Spasticity Due to Cerebral Palsy1
3CompletedTreatmentLower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy1
3CompletedTreatmentMigraine Disorders3
3CompletedTreatmentModerate to Severe Glabellar Line1
3CompletedTreatmentMuscle Spasticity1
3CompletedTreatmentMyofascial Pain Syndromes1
3CompletedTreatmentNervous System Disorders2
3CompletedTreatmentNeurogenic Detrusor Overactivity1
3CompletedTreatmentNotalgia Paresthetica1
3CompletedTreatmentOther Infantile Cerebral Palsy1
3CompletedTreatmentOveractive Bladder5
3CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)2
3CompletedTreatmentPost-stroke Spasticity of the Lower Limb1
3CompletedTreatmentPost-stroke Spasticity of the Upper Limb1
3CompletedTreatmentPost-stroke Upper Limb Spasticity1
3CompletedTreatmentRaynaud's Syndrome / Scleroderma1
3CompletedTreatmentRefractory Urge Urinary Incontinence / Urinary Incontinence, Urge1
3CompletedTreatmentSkin Aging5
3CompletedTreatmentSpasticity1
3CompletedTreatmentSpasticity Post-Traumatic Brain Injury / Spasticity, Post-Stroke1
3CompletedTreatmentSpasticity of the Upper and Lower Limb Due to Cerebral Causes1
3CompletedTreatmentSpasticity, Post-Stroke1
3CompletedTreatmentSpasticity / Strokes2
3CompletedTreatmentStrabismus1
3CompletedTreatmentUpper Limb Spasticity1
3CompletedTreatmentFacial fine wrinkling1
3Enrolling by InvitationTreatmentChronic Migraine1
3Enrolling by InvitationTreatmentOveractive Bladder1
3Not Yet RecruitingTreatmentAcquired Esotropia1
3Not Yet RecruitingTreatmentCerebral Palsy (CP)1
3Not Yet RecruitingTreatmentCerebrovascular Accidents1
3Not Yet RecruitingTreatmentMyofascial Pain Syndrome / Pain Syndrome / Pain, Head / Temporomandibular Disorders1
3Not Yet RecruitingTreatmentObstetrical Brachial Plexus Palsy1
3Not Yet RecruitingTreatmentTrigeminal Neuropathy, Traumatic1
3RecruitingPreventionIntercanthal Distance Ratio / Scarring1
3RecruitingTreatmentCerebral Palsy (CP)1
3RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics1
3RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity / Pediatrics / Strokes1
3RecruitingTreatmentCerebrovascular Accidents1
3RecruitingTreatmentCrow's Feet Lines2
3RecruitingTreatmentHyperhidrosis / Residual Limbs1
3RecruitingTreatmentLateral Epicondylitis1
3RecruitingTreatmentMuscle Spasticity1
3RecruitingTreatmentOveractive Bladder1
3RecruitingTreatmentOveractive Bladder / Urinary Incontinence (UI)2
3RecruitingTreatmentStrokes2
3RecruitingTreatmentTrigeminal Neuralgia (TN)1
3RecruitingTreatmentUrinary Bladder, Overactive / Urinary Incontinence (UI)1
3RecruitingTreatmentUrinary Incontinence (UI)1
3RecruitingTreatmentVestibulodynia1
3RecruitingTreatmentVulvodynia1
3TerminatedTreatmentChronic Post Traumatic Headache1
3TerminatedTreatmentChronic Prostatitis With Chronic Pelvic Pain Syndrome / Prostatitis1
3TerminatedTreatmentDetrusor Hyperreflexia / Overactive Bladder / Urge Incontinence / Urinary Incontinence (UI) / Urinary Urge Incontinence1
3TerminatedTreatmentDetrusor Overactivity / Urge Urinary Incontinence / Urinary Incontinence (UI) / Urination urgency of1
3TerminatedTreatmentLower Urinary Tract Discomfort / Stent Pain1
3TerminatedTreatmentMuscle Spasticity / Strokes1
3TerminatedTreatmentOveractive Bladder1
3TerminatedTreatmentPatellofemoral Pain Syndrome1
3TerminatedTreatmentSkin Aging1
3Unknown StatusTreatmentHemiplegic Patients Post-AVC1
3Unknown StatusTreatmentOveractive Bladder1
3Unknown StatusTreatmentScarring1
3Unknown StatusTreatmentFacial fine wrinkling1
3WithdrawnNot AvailableNeurocostal neuralgia / Pain Due to Certain Specified Procedures / Pain, Neuropathic1
3WithdrawnPreventionMigraine Disorders2
3WithdrawnTreatmentMuscle Spasticity / Strokes1
4Active Not RecruitingTreatmentBlepharospasm / Botulinum Toxins, Type A / Hemifacial Spasm1
4Active Not RecruitingTreatmentChronic Idiopathic Constipation / Functional Constipation1
4Active Not RecruitingTreatmentParkinson's Disease (PD)1
4Active Not RecruitingTreatmentSpastic Hemiplegia1
4Active Not RecruitingTreatmentUrinary Bladder, Overactive / Urinary Incontinence (UI)1
4CompletedNot AvailableHealthy Subjects, Only With Wrinkles on Forehead1
4CompletedNot AvailableMigraine Disorders1
4CompletedNot AvailableUrinary Bladder, Overactive1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedPreventionMigraine Disorders1
4CompletedPreventionOveractive Bladder / Painful Bladder Syndrome (PBS) / Urinary Bladder, Neurogenic / Urinary Urge Incontinence1
4CompletedPreventionStrokes / Upper Limb Spasticity1
4CompletedTreatmentAging1
4CompletedTreatmentBlepharospasm1
4CompletedTreatmentBrain Injury / Spasticity Secondary to Either a Disorder or Trauma / Spinal Cord Injuries (SCI) / Strokes / Tumors1
4CompletedTreatmentBrain Injury / Spasticity / Strokes1
4CompletedTreatmentBrow Ptosis1
4CompletedTreatmentBrow Ptosis / Lid Ptosis1
4CompletedTreatmentCerebral Palsy (CP)1
4CompletedTreatmentCerebral Palsy and Botulinum Toxin1
4CompletedTreatmentCerebrovascular Accidents / Muscle Spasticity2
4CompletedTreatmentCervical Dystonia4
4CompletedTreatmentChronic Migraine5
4CompletedTreatmentCrow's Feet Lines / Facial Rhytides / Glabellar Lines / Nasolabial Folds1
4CompletedTreatmentDiabetic Polyneuropathies / Other Polyneuropathies / Postherpetic Neuralgia1
4CompletedTreatmentDisseminated Sclerosis / Muscle Spasticity1
4CompletedTreatmentEsotropia / Exotropia1
4CompletedTreatmentEssential Blepharospasm1
4CompletedTreatmentFacial Asymmetry / Facial Nerve Injuries / Facial Paresis Associated With Facial Nerve Dysfunction / Synkinesis1
4CompletedTreatmentFacial Rhytides1
4CompletedTreatmentGlabellar Frown Lines3
4CompletedTreatmentGlabellar Furrows1
4CompletedTreatmentGlabellar Lines1
4CompletedTreatmentGlabellar Rhytides1
4CompletedTreatmentHallux Valgus1
4CompletedTreatmentHyperhidrosis2
4CompletedTreatmentInterstitial Cystitis1
4CompletedTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
4CompletedTreatmentIntrinsic Aging of Skin / Solar Elastosis1
4CompletedTreatmentMigraine Disorders2
4CompletedTreatmentMild to Moderate Temporal Atrophy / Moderate to Severe Glabellar Rhytids / Moderate to Severe Periorbital Rhytids1
4CompletedTreatmentMuscle Spasticity1
4CompletedTreatmentOveractive Bladder1
4CompletedTreatmentOveractive Bladder / Urinary Incontinence (UI)1
4CompletedTreatmentPain, Neuropathic / Spinal Cord Injuries (SCI)1
4CompletedTreatmentPlantar Fascitis1
4CompletedTreatmentSkin Aging1
4CompletedTreatmentSpasmodic Torticollis1
4CompletedTreatmentSpastic Hemiplegia / Spasticity as Sequela of Stroke / Strokes1
4CompletedTreatmentSpasticity1
4CompletedTreatmentStroke Rehabilitation / Stroke Rehabilitation Spasticity Management1
4CompletedTreatmentSun-induced Wrinkles1
4CompletedTreatmentTorticollis1
4CompletedTreatmentUpper Limb Spasticity1
4CompletedTreatmentWrinkles in Frontal Area1
4CompletedTreatmentFacial fine wrinkling1
4Not Yet RecruitingTreatmentActivity / Pain1
4Not Yet RecruitingTreatmentEquinovarus; Acquired1
4Not Yet RecruitingTreatmentOveractive Bladder / Overactive Bladder Syndrome / Urinary Bladder, Overactive / Urinary Frequency/Urgency / Urinary Incontinence (UI) / Urination urgency of1
4RecruitingBasic ScienceMigraines1
4RecruitingOtherMuscle Spasticity / Strokes1
4RecruitingPreventionOther Degenerative Disorders of Eyelid and Periocular Area1
4RecruitingTreatmentBreast Diseases / Neoplasms / Neoplasms by Site / Neoplasms, Breast / Skin Diseases1
4RecruitingTreatmentBrow Lifting1
4RecruitingTreatmentCerebral Palsy (CP) / Muscle Spasticity1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentMixed Urinary Incontinence / Stress Urinary Incontinence (SUI) / Urgency Incontinence1
4RecruitingTreatmentPain, Face1
4RecruitingTreatmentPainful Intercourse / Pelvic Floor Dysfunctions / Pelvic Pain1
4RecruitingTreatmentScarring1
4RecruitingTreatmentSpasticity1
4RecruitingTreatmentSpinal Cord Injuries (SCI) / Urinary Bladder, Overactive1
4TerminatedTreatmentAnxiety Disorder Social / Feeling Anxious1
4TerminatedTreatmentArthritis Multiple Joint / Basal Thumb Joint Arthritis / Basilar Joint Arthritis / Carpometacarpal Arthritis / Trapeziometacarpal Arthritis1
4TerminatedTreatmentChronic Male Pelvic Pain Syndrome1
4TerminatedTreatmentLow Back Pain (LBP)1
4TerminatedTreatmentParkinson's Disease (PD)1
4TerminatedTreatmentSpasmodic Torticollis1
4Unknown StatusPreventionAutonomic Dysreflexia1
4Unknown StatusTreatmentBruxism1
4Unknown StatusTreatmentCatocholamine Induced Finger Necrosis1
4Unknown StatusTreatmentChronic Low Back Pain (CLBP)1
4Unknown StatusTreatmentElastosis Senilis / Skin Aging1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMuscle Spasticity1
4Unknown StatusTreatmentOveractive Detrusor1
4Unknown StatusTreatmentSleep Bruxism1
4WithdrawnTreatmentFoot Deformities / Leg Length Inequality1
4WithdrawnTreatmentGraves Ophthalmopathy1
Not AvailableActive Not RecruitingTreatmentFacial Flushing1
Not AvailableActive Not RecruitingTreatmentHeadaches1
Not AvailableActive Not RecruitingTreatmentIdiopathic Clubfoot (Talipes Equinovarus)1
Not AvailableActive Not RecruitingTreatmentMyofascial Pelvic Pain1
Not AvailableActive Not RecruitingTreatmentPelvic Pain1
Not AvailableActive Not RecruitingTreatmentFacial fine wrinkling1
Not AvailableCompletedNot AvailableBlepharospasm / Cervical Dystonia1
Not AvailableCompletedNot AvailableCerebral Palsy (CP)1
Not AvailableCompletedNot AvailableChronic Migraine, Headaches1
Not AvailableCompletedNot AvailableCrow's Feet Lines / Lateral Canthal Lines1
Not AvailableCompletedNot AvailableFacial Rhytides1
Not AvailableCompletedNot AvailableGlabellar Lines1
Not AvailableCompletedNot AvailableGlabellar Lines / Hyperhidrosis / Muscle Spasticity1
Not AvailableCompletedNot AvailableHeadaches / Migraine Disorders1
Not AvailableCompletedNot AvailableLower Limb Spasticity1
Not AvailableCompletedNot AvailableMigraine Disorders1
Not AvailableCompletedNot AvailableMumps1
Not AvailableCompletedNot AvailableMuscle Spasticity2
Not AvailableCompletedNot AvailableOveractive Bladder / Urinary Incontinence (UI)1
Not AvailableCompletedNot AvailableSkin Laxity1
Not AvailableCompletedNot AvailableSpasticity, Post-Stroke1
Not AvailableCompletedNot AvailableTorticollis1
Not AvailableCompletedNot AvailableUrinary Bladder, Neurogenic / Urinary Bladder, Overactive1
Not AvailableCompletedNot AvailableUrinary Bladder, Overactive / Urinary Incontinence (UI)2
Not AvailableCompletedNot AvailableUrinary Incontinence (UI)1
Not AvailableCompletedDiagnosticBotulinum Toxins, Type A / Normal, Healthy Volunteers / Strength, Muscle1
Not AvailableCompletedHealth Services ResearchHealthy Volunteers1
Not AvailableCompletedHealth Services ResearchMuscle Spasticity / Strokes1
Not AvailableCompletedPreventionHerpes Labialis1
Not AvailableCompletedPreventionPost Traumatic Stiffness1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedTreatmentAchalasia, Esophageal1
Not AvailableCompletedTreatmentAxillary Hyperhidrosis1
Not AvailableCompletedTreatmentCerebral Palsy (CP) / Muscle Spasticity1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Pain, Neuropathic1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Peripheral Neuropathy / Plantar Ulcers1
Not AvailableCompletedTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentFacial Rhytides / Glabellar Frown Lines1
Not AvailableCompletedTreatmentFacial Wrinkles1
Not AvailableCompletedTreatmentHIV Posterior Cheek Enlargement1
Not AvailableCompletedTreatmentHyperhidrosis1
Not AvailableCompletedTreatmentIdiopathic Clubfoot (Talipes Equinovarus)1
Not AvailableCompletedTreatmentKeratoconus1
Not AvailableCompletedTreatmentNon-neurogenic / Urinary Urge Incontinence1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentPost-stroke Shoulder Pain and Spasticity1
Not AvailableCompletedTreatmentPrimary Axillary Hyperhidrosis1
Not AvailableCompletedTreatmentRaynaud's Syndrome1
Not AvailableCompletedTreatmentSkin Wrinklings1
Not AvailableCompletedTreatmentSpastic Equinovarus1
Not AvailableCompletedTreatmentSubacute Cervical Pain / Subacute Upper Back Pain1
Not AvailableCompletedTreatmentTremor, Essential1
Not AvailableCompletedTreatmentUrinary Incontinence (UI)1
Not AvailableCompletedTreatmentVaginismus1
Not AvailableEnrolling by InvitationNot AvailableUnilateral Spastic Cerebral Palsy1
Not AvailableNot Yet RecruitingNot AvailableDysphonia1
Not AvailableRecruitingNot AvailableCerebral Palsy (CP)1
Not AvailableRecruitingNot AvailableDetrusor, Overactive / Disseminated Sclerosis / Lower Urinary Tract Symptoms (LUTS) / Neurogenic Bladder Dysfunction / Urge Incontinence1
Not AvailableRecruitingNot AvailableEsthetic Outcome of Injection of Botulinum Toxin Type-A in Cleft Lip Repair1
Not AvailableRecruitingNot AvailableLower Limb Spasticity1
Not AvailableRecruitingNot AvailableMixed Incontinence, Urge and Stress1
Not AvailableRecruitingNot AvailableUrinary Bladder, Overactive1
Not AvailableRecruitingTreatmentChronic Vocal Tic / Gilles de la Tourette's Syndrome1
Not AvailableRecruitingTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
Not AvailableRecruitingTreatmentGingival Exposure1
Not AvailableRecruitingTreatmentHemifacial Spasm1
Not AvailableRecruitingTreatmentMigrainous Headache1
Not AvailableRecruitingTreatmentPlantar fascial fibromatosis1
Not AvailableSuspendedTreatmentPain1
Not AvailableTerminatedNot AvailableCerebral Palsy (CP)1
Not AvailableTerminatedTreatmentBrain Injury / Stiff Knee Gait1
Not AvailableTerminatedTreatmentEquinus Contracture1
Not AvailableTerminatedTreatmentErythema and Flushing Associated With Rosacea1
Not AvailableTerminatedTreatmentMigrainous Headache1
Not AvailableTerminatedTreatmentTransient ischemia attacks / Vasopressor1
Not AvailableUnknown StatusTreatmentAlopecia Areata (AA)1
Not AvailableUnknown StatusTreatmentEsophageal Spasm, Diffuse1
Not AvailableUnknown StatusTreatmentFlexion Contracture Following Total Knee Replacement1
Not AvailableUnknown StatusTreatmentLateral Epicondylitis / Type A Botulinum Toxin1
Not AvailableWithdrawnNot AvailableChronic Migraine, Headaches1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Allergan Inc.
  • Tercica Inc.
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntradermal; Intramuscular100 [USP'U]/1
Injection, powder, lyophilized, for solutionIntradermal; Intramuscular200 [USP'U]/1
Powder, for solutionIntramuscular100 unit
Injection, powder, lyophilized, for solutionIntramuscular300 U/1
Injection, powder, lyophilized, for solutionIntramuscular500 U/1
Powder, for solutionIntramuscular300 unit
Powder, for solutionIntramuscular500 unit
GelTopical10 g/10mL
Injection, powder, lyophilized, for solutionIntramuscular100 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular200 [USP'U]/1
Injection, powder, lyophilized, for solutionIntramuscular50 [USP'U]/1
Powder, for solutionIntramuscular50 unit
Prices
Unit descriptionCostUnit
Botox 200 unit vial1260.0USD vial
Dysport 500 unit vial852.0USD vial
Botox 100 unit655.2USD vial
Botox 100 unit vial630.0USD vial
Botox cosmetic 100 unit vial630.0USD vial
Botox cosmetic 50 unit vial346.8USD vial
Botox (100 - 200 unit/Vial)3.74USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2280565No2005-11-152019-08-20Canada
CA2310845No2001-05-152014-06-07Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
hydrophobicity-0.368Not Available
isoelectric point6.06Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Syntaxin-1 binding
Specific Function
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesi...
Gene Name
SNAP25
Uniprot ID
P60880
Uniprot Name
Synaptosomal-associated protein 25
Molecular Weight
23314.905 Da
References
  1. Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9. [PubMed:14644446]
  2. Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii. [PubMed:15222581]
  3. Okada M, Yoshida S, Zhu G, Kaneko S: [Methodological consideration in studying the exocytosis mechanisms using microdialysis]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Aug;24(4):165-70. [PubMed:15484814]
  4. Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M: Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131(4):813-23. [PubMed:15749336]
  5. Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13. [PubMed:16831062]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Gtpase activity
Specific Function
Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative r...
Gene Name
RHOB
Uniprot ID
P62745
Uniprot Name
Rho-related GTP-binding protein RhoB
Molecular Weight
22123.185 Da
References
  1. Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12. [PubMed:15140914]

Drug created on June 13, 2005 07:24 / Updated on June 23, 2018 21:10